Cardiac Remodeling Biomarker Potentially Identifies High Risk Patients with PAH

In the a post hoc analysis of the 24-week open-label, uncontrolled Phase 3B clinical trial RESPITE researchers assessed ST-2 as a biomarker of the likelihood response in patients who switched from PDE5 inhibitors to riociguat as well as the association of ST-2 with the REVEAL risk score. Suppressor of tumorigenicity (ST-2) may function as a biomarker to identify patients with pulmonary arterial hypertension (PAH) with higher REVEAL risk scores, according to research being presented at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation held in Orlando, Florida.